Peptide number . | Peptide sequence . | COVID-19 acute . | COVID-19 convalescents . | Pre-pandemic . |
---|---|---|---|---|
1 | MSDNGPQNQRNAPRITFGGP | *** | * | ns |
2 | RPQGLPNNTASWFTALTQHG | ns | ns | ns |
3 | IGYYRRATRRIRGGDGKMKD | ** | ns | * |
4 | LNTPKDHIGTRNPANNAAIV | ns | ns | ns |
5 | GSQASSRSSSRSRNSSRNST | ** | ns | ns |
6 | NQLESKMSGKGQQQQGQTVT | ns | ns | ns |
7 | RRGPEQTQGNFGDQELIRQG | ns | ns | ns |
8 | IAQFAPSASAFFGMSRIGME | ns | ns | ns |
9 | SDSTGSNQNGERSGARSKQR | **** | ns | ** |
10 | LKFPRGQGVPINTNSSPDDQ | ns | ns | ns |
11 | GTGPEAGLPYGANKDGIIWV | ns | ns | ns |
12 | LQLPQGTTLPKGFYAEGSRG | ns | ns | ns |
13 | TPGSSRGTSPARMAGNGGDA | ns | ns | ns |
14 | KKSAAEASKKPRQKRTATKA | **** | * | **** |
15 | GDQELIRQGTDYKHWPQIAQ | ns | ns | ns |
16 | DPNFKDQVILLNKHIDAYKT | ns | ns | ns |
17 | FPPTEPKKDKKKKADETQAL | * | ns | ns |
18 | LDDFSKQLQQSMSSADSTQA | ns | ns | ns |
19 | KADETQALPQRQKKQQTVTL | ** | *** | ns |
20 | GDAALALLLLDRLNQLESKM | ns | ns | ns |
Peptide number . | Peptide sequence . | COVID-19 acute . | COVID-19 convalescents . | Pre-pandemic . |
---|---|---|---|---|
1 | MSDNGPQNQRNAPRITFGGP | *** | * | ns |
2 | RPQGLPNNTASWFTALTQHG | ns | ns | ns |
3 | IGYYRRATRRIRGGDGKMKD | ** | ns | * |
4 | LNTPKDHIGTRNPANNAAIV | ns | ns | ns |
5 | GSQASSRSSSRSRNSSRNST | ** | ns | ns |
6 | NQLESKMSGKGQQQQGQTVT | ns | ns | ns |
7 | RRGPEQTQGNFGDQELIRQG | ns | ns | ns |
8 | IAQFAPSASAFFGMSRIGME | ns | ns | ns |
9 | SDSTGSNQNGERSGARSKQR | **** | ns | ** |
10 | LKFPRGQGVPINTNSSPDDQ | ns | ns | ns |
11 | GTGPEAGLPYGANKDGIIWV | ns | ns | ns |
12 | LQLPQGTTLPKGFYAEGSRG | ns | ns | ns |
13 | TPGSSRGTSPARMAGNGGDA | ns | ns | ns |
14 | KKSAAEASKKPRQKRTATKA | **** | * | **** |
15 | GDQELIRQGTDYKHWPQIAQ | ns | ns | ns |
16 | DPNFKDQVILLNKHIDAYKT | ns | ns | ns |
17 | FPPTEPKKDKKKKADETQAL | * | ns | ns |
18 | LDDFSKQLQQSMSSADSTQA | ns | ns | ns |
19 | KADETQALPQRQKKQQTVTL | ** | *** | ns |
20 | GDAALALLLLDRLNQLESKM | ns | ns | ns |
Immunoreactivity of each sequence in the group was tested against the threshold calculated for the whole group using one-way ANOVA and the Dunnett’s multiple comparison test (α = 0.05): *P < .05; **P < .01; ***P < .001; ****P < .0001.
Peptide number . | Peptide sequence . | COVID-19 acute . | COVID-19 convalescents . | Pre-pandemic . |
---|---|---|---|---|
1 | MSDNGPQNQRNAPRITFGGP | *** | * | ns |
2 | RPQGLPNNTASWFTALTQHG | ns | ns | ns |
3 | IGYYRRATRRIRGGDGKMKD | ** | ns | * |
4 | LNTPKDHIGTRNPANNAAIV | ns | ns | ns |
5 | GSQASSRSSSRSRNSSRNST | ** | ns | ns |
6 | NQLESKMSGKGQQQQGQTVT | ns | ns | ns |
7 | RRGPEQTQGNFGDQELIRQG | ns | ns | ns |
8 | IAQFAPSASAFFGMSRIGME | ns | ns | ns |
9 | SDSTGSNQNGERSGARSKQR | **** | ns | ** |
10 | LKFPRGQGVPINTNSSPDDQ | ns | ns | ns |
11 | GTGPEAGLPYGANKDGIIWV | ns | ns | ns |
12 | LQLPQGTTLPKGFYAEGSRG | ns | ns | ns |
13 | TPGSSRGTSPARMAGNGGDA | ns | ns | ns |
14 | KKSAAEASKKPRQKRTATKA | **** | * | **** |
15 | GDQELIRQGTDYKHWPQIAQ | ns | ns | ns |
16 | DPNFKDQVILLNKHIDAYKT | ns | ns | ns |
17 | FPPTEPKKDKKKKADETQAL | * | ns | ns |
18 | LDDFSKQLQQSMSSADSTQA | ns | ns | ns |
19 | KADETQALPQRQKKQQTVTL | ** | *** | ns |
20 | GDAALALLLLDRLNQLESKM | ns | ns | ns |
Peptide number . | Peptide sequence . | COVID-19 acute . | COVID-19 convalescents . | Pre-pandemic . |
---|---|---|---|---|
1 | MSDNGPQNQRNAPRITFGGP | *** | * | ns |
2 | RPQGLPNNTASWFTALTQHG | ns | ns | ns |
3 | IGYYRRATRRIRGGDGKMKD | ** | ns | * |
4 | LNTPKDHIGTRNPANNAAIV | ns | ns | ns |
5 | GSQASSRSSSRSRNSSRNST | ** | ns | ns |
6 | NQLESKMSGKGQQQQGQTVT | ns | ns | ns |
7 | RRGPEQTQGNFGDQELIRQG | ns | ns | ns |
8 | IAQFAPSASAFFGMSRIGME | ns | ns | ns |
9 | SDSTGSNQNGERSGARSKQR | **** | ns | ** |
10 | LKFPRGQGVPINTNSSPDDQ | ns | ns | ns |
11 | GTGPEAGLPYGANKDGIIWV | ns | ns | ns |
12 | LQLPQGTTLPKGFYAEGSRG | ns | ns | ns |
13 | TPGSSRGTSPARMAGNGGDA | ns | ns | ns |
14 | KKSAAEASKKPRQKRTATKA | **** | * | **** |
15 | GDQELIRQGTDYKHWPQIAQ | ns | ns | ns |
16 | DPNFKDQVILLNKHIDAYKT | ns | ns | ns |
17 | FPPTEPKKDKKKKADETQAL | * | ns | ns |
18 | LDDFSKQLQQSMSSADSTQA | ns | ns | ns |
19 | KADETQALPQRQKKQQTVTL | ** | *** | ns |
20 | GDAALALLLLDRLNQLESKM | ns | ns | ns |
Immunoreactivity of each sequence in the group was tested against the threshold calculated for the whole group using one-way ANOVA and the Dunnett’s multiple comparison test (α = 0.05): *P < .05; **P < .01; ***P < .001; ****P < .0001.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.